0001213900-22-060782.txt : 20220930 0001213900-22-060782.hdr.sgml : 20220930 20220930172051 ACCESSION NUMBER: 0001213900-22-060782 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220929 FILED AS OF DATE: 20220930 DATE AS OF CHANGE: 20220930 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: THURMAN RANDY H CENTRAL INDEX KEY: 0001204059 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39102 FILM NUMBER: 221284996 MAIL ADDRESS: STREET 1: 222 MERCHANDISE MART PLAZA STREET 2: SUITE 2024 CITY: CHICAGO STATE: IL ZIP: 60654 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TFF Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001733413 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 824344737 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2600 VIA FORTUNA, SUITE 360 CITY: AUSTIN STATE: TX ZIP: 78746 BUSINESS PHONE: 737-802-1973 MAIL ADDRESS: STREET 1: 2600 VIA FORTUNA, SUITE 360 CITY: AUSTIN STATE: TX ZIP: 78746 4 1 ownership.xml X0306 4 2022-09-29 0 0001733413 TFF Pharmaceuticals, Inc. TFFP 0001204059 THURMAN RANDY H 1751 RIVER RUN, SUITE 400 FORT WORTH TX 76107 1 0 0 0 Common Stock 2022-09-29 4 M 0 40255 2.50 A 40255 D Common Stock 2022-09-29 4 S 0 40255 4.29 D 0 D Stock Options (Right to Buy) 2.50 2022-09-29 4 M 0 40255 0.000 D 2019-04-11 2029-04-11 Common Stock 40255 84670 D The reported shares were sold in the open market in multiple transactions at prices ranging from $4.18 to $4.57. The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to TFF Pharmaceuticals, Inc., any stockholder of TFF Pharmaceuticals, Inc or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options. /s/ Randy Thurman, by Kirk Allen Coleman, as Attorney-in-Fact 2022-09-30